Plus Therapeutics, Inc. announced on December 3, 2024, the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. This agreement secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda.
This continuing agreement builds on the company's comprehensive supply chain strategy, which also includes a partnership with SpectronRx for final drug manufacturing. The goal is to establish a scalable, end-to-end supply chain.
Securing the supply of Re-186 is crucial for meeting the demands of late-stage clinical trials and future commercial needs. The agreement also includes the production of aluminum perrhenate, a key radionuclide intermediate, and final processing of cGMP Re-186.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.